Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Estrogen Receptor Positive × palbociclib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 5 Pancreatic Neoplasms 2 Ovarian Neoplasms 2 Sarcoma 1 Prostatic Neoplasms 1 Neoplasms 1 Neoplasm Metastasis 1 Lymphoma, Follicular 1 Fallopian Tube Neoplasms 1 Estrogen Receptor Positive 1 Colorectal Neoplasms 1 Carcinoma, Endometrioid 1 COVID-19 1 Brain Neoplasms 1 Adenocarcinoma of Lung 1

Interventions

palbociclib 1 copanlisib 1 Fulvestrant 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03377101 2018-08-14

Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast Cancer

National Cancer Institute (NCI)

Phase 2 Withdrawn

Estrogen Receptor Positive

Data powered by HemOnc (CC BY 4.0) Colophon ⚡